Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERSE-AR: Sacubitril/Valsartan vs. Amlodipine/Losartan in Aortic Regurgitation
NCT05212597Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sacubitril + valsartan in aortic valve insufficiency (AI), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
sacubitril + valsartan
03
Conditions
aortic valve insufficiency (AI)
Beyond the preview
Go deeper on NCT05212597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05212597.